triple-negative breast cancer tagged posts

ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis. Proceedings of the National Academy of Sciences, 2018; 201807751 DOI: 10.1073/pnas.1807751115

Mayo Clinic researchers have identified the drug estradiol as a potential new treatment for a subset of women with triple-negative breast cancer. Their findings are published in the Proceedings of the National Academy of Sciences.

“Triple-negative breast cancer is a form of breast cancer that lacks expression of estrogen receptor alpha, progesterone receptor, and human epidermal growth factor receptor 2, also known as HER2. And it exhibits high rates of disease recurrence,” says John Hawse, Ph.D., a molecular biologist at Mayo Clinic and senior author...

Extracellular asparagine availability drives invasion and metastasis.

A single protein building block commonly found in food may hold a key to preventing the spread of an often-deadly type of breast cancer, according to a new multicenter study published today in the medical journal Nature. Investigators found that by limiting an amino acid called asparagine in laboratory mice with triple-negative breast cancer, they could dramatically reduce the ability of the cancer to travel to distant sites in the body. Among other techniques, the team used dietary restrictions to limit asparagine.

Foods rich in asparagine include dairy, whey, beef, poultry, eggs, fish, seafood, asparagus, potatoes, legumes, nuts, seeds, soy and whole grains. Foods low in asparagine include most fruits and vegetables...

CDK4/6 inhibition inhibits cancer metastasis.

Breast cancer metastasis, the process by which cancer spreads, may be prevented through the new use of a class of drugs already approved by the FDA. Mayo Clinic researchers have identified that a key drug target, CDK4/6, regulates a cancer metastasis protein, SNAIL, and drugs that inhibit CDK 4/6 could prevent the spread of triple-negative breast cancer. CDK4/6 inhibitors are approved for treating estrogen positive breast cancer, but not triple-negative breast cancer.

For this study, Dr. Lou and his colleagues focused on triple-negative breast cancer, which is difficult to treat, because it does not exhibit receptors for estrogen, progesterone or the HER-2/neu gene, which are targets for many current breast cancer treatments...

Live cell imaging shows fluorescently labeled targeted ZnO nanoparticles (green) dissolving to release zinc ions (blue) within the intracellular environment of triple-negative breast cancer cells, activating cell death pathways (red). © 2016 KAUST

Zinc oxide (ZnO) nanoparticles may help destroy difficult-to-treat triple-negative breast cancer tumors. Breast tumors that are so-called triple-negative are largely resistant to existing cancer drugs, giving patients an especially poor prognosis. Researchers at King Abdullah University of Science and Technology (KAUST), Saudi Arabia, and collaborators are now exploring a potential therapeutic option for such tumors that is based on the tumor-specific effects of zinc oxide (ZnO) nanoparticles.

Previous studies have shown ZnO treatment can kill c...